Advertisement

Targeted Oncology

, Volume 14, Issue 6, pp 759–768 | Cite as

Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC

  • Sohita Dhillon
  • Yahiya Y. SyedEmail author
Adis Drug Evaluation

Abstract

Atezolizumab (Tecentriq®), a humanized, anti-programmed cell death ligand-1 (PD-L1) monoclonal antibody, in combination with bevacizumab, carboplatin and paclitaxel (ABCP) or with carboplatin and nab-paclitaxel (ACnP) has been approved as first-line treatment for metastatic nonsquamous NSCLC, based on results from the randomized IMpower150 and IMpower130 studies in chemotherapy-naïve patients with nonsquamous metastatic NSCLC. In IMpower150, ABCP prolonged progression-free survival (PFS) and overall survival (OS) relative to BCP, regardless of EGFR or ALK status, liver metastases at baseline or PD-L1 expression levels. In IMpower130, ACnP prolonged PFS and OS relative to CnP in patients without EGFR or ALK genetic aberrations. ABCP and ACnP had manageable tolerability profiles, which were consistent with the profile of the individual components of the regimen. Immune-related adverse events with ABCP and ACnP were largely mild or moderate in severity, and most were reversible with interruption of atezolizumab and initiation of appropriate treatment. Current evidence indicates that ABCP and ACnP are valuable emerging first-line treatment options for metastatic nonsquamous NSCLC.

Notes

Acknowledgements

During the peer review process the manufacturer of atezolizumab was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Sohita Dhillon and Yahiya Syed are salaried employees of Adis International Ltd/Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.

References

  1. 1.
    Peters S, Reck M, Smit EF, et al. How to make the best use of immunotherapy as first-line treatment for advanced/metastatic non-small-cell lung cancer. Ann Oncol. 2019.  https://doi.org/10.1093/annonc/mdz109.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol. 2017;47(5):765–79.CrossRefGoogle Scholar
  3. 3.
    Khan M, Lin J, Liao G, et al. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97(33):e11936.CrossRefGoogle Scholar
  4. 4.
    Huang Q, Zhang H, Hai J, et al. Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: a meta-analysis of randomized trials. Oncoimmunology. 2018;7(12):e1396403.CrossRefGoogle Scholar
  5. 5.
    Meyers DE, Bryan PM, Banerji S, et al. Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer. Curr Oncol. 2018;25(4):e324–34.CrossRefGoogle Scholar
  6. 6.
    Sui H, Ma N, Wang Y, et al. Anti-PD-1/PD-L1 therapy for non-small-cell lung cancer: toward personalized medicine and combination strategies. J Immunol Res. 2018;2018:6984948.CrossRefGoogle Scholar
  7. 7.
    Manegold C, Dingemans AC, Gray JE, et al. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J Thorac Oncol. 2017;12(2):194–207.CrossRefGoogle Scholar
  8. 8.
    Doroshow DB, Sanmamed MF, Hastings K, et al. Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res. 2019.  https://doi.org/10.1158/1078-0432.CCR-18-1538.CrossRefPubMedGoogle Scholar
  9. 9.
    Herbst RS, Sznol M. Diminished but not dead: chemotherapy for the treatment of NSCLC. Lancet Oncol. 2016;17(11):1464–5.CrossRefGoogle Scholar
  10. 10.
    Voron T, Marcheteau E, Pernot S, et al. Control of the immune response by pro-angiogenic factors. Front Oncol. 2014;4:70.CrossRefGoogle Scholar
  11. 11.
    Dumoulin D, De Goeje P, Poncin M, et al. Paclitaxel/carboplatin/bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors [abstract no. 22P]. Ann Oncol. 2019;30(Suppl 2):ii7.Google Scholar
  12. 12.
    Roche. Tecentriq (atezolizumab): EU summary of product characteristics. 2019. https://www.ema.europa.eu. Accessed 8 July 2019.
  13. 13.
    Genentech Inc. TECENTRIQ® (atezolizumab): US prescribing information. 2019. https://www.gene.com. Accessed 8 July 2019.
  14. 14.
    Chugai Pharmaceutical Co. Ltd. Tecentric intravenous infusion 840 mg/1200 mg: Japanese prescribing information. 2019. http://www.pmda.go.jp. Accessed 11 Oct 2019.
  15. 15.
    Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7.CrossRefGoogle Scholar
  16. 16.
    Akbari O, Stock P, Singh AK, et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol. 2010;3(1):81–91.CrossRefGoogle Scholar
  17. 17.
    Facchinetti F, Bordi P, Leonetti A, et al. Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. Drug Des Dev Ther. 2018;12:2857–73.CrossRefGoogle Scholar
  18. 18.
    Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–301.CrossRefGoogle Scholar
  19. 19.
    Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7(5):387–401.CrossRefGoogle Scholar
  20. 20.
    West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924–37.CrossRefGoogle Scholar
  21. 21.
    Myers G. Immune-related adverse events of immune checkpoint inhibitors: a brief review. Curr Oncol. 2018;25(5):342–7.CrossRefGoogle Scholar
  22. 22.
    Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl. 4):iv192–237.CrossRefGoogle Scholar
  23. 23.
    Wu YL, Planchard D, Lu S, et al. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30(2):171–210.CrossRefGoogle Scholar
  24. 24.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer (Version 7). 2019. https://www.nccn.org. Accessed 2 Oct 2019.
  25. 25.
    National Institute of Health and Care Excellence. Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer. 2019. https://www.nice.org.uk. Accessed 8 July 2019.
  26. 26.
    Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65.CrossRefGoogle Scholar
  27. 27.
    Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.CrossRefGoogle Scholar
  28. 28.
    Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.CrossRefGoogle Scholar
  29. 29.
    Tumeh PC, Hellmann MD, Hamid O, et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res. 2017;5(5):417–24.CrossRefGoogle Scholar
  30. 30.
    Barlesi F, Nishio M, Cobo M, et al. IMpower132: efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC) [abstract no. LBA54]. Ann Oncol. 2018.  https://doi.org/10.1093/annonc/mdy424.066.CrossRefPubMedGoogle Scholar
  31. 31.
    Dafni U, Tsourti Z, Vervita K, et al. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Lung Cancer. 2019;134:127–40.CrossRefGoogle Scholar
  32. 32.
    Frederickson AM, Arndorfer S, Zhang I, et al. Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis. Immunotherapy. 2019;11(5):407–28.CrossRefGoogle Scholar
  33. 33.
    Wan X, Luo X, Tan C, et al. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: a United States-based cost-effectiveness analysis. Cancer. 2019;125(20):3526–34.CrossRefGoogle Scholar
  34. 34.
    Criss SD, Mooradian MJ, Watson TR, et al. Cost-effectiveness of atezolizumab combination therapy for first-line treatment of metastatic nonsquamous non-small cell lung cancer in the United States. JAMA Netw Open. 2019.  https://doi.org/10.1001/jamanetworkopen.2019.11952.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations